Open AccessNewly diagnosed breast cancer in a patient receiving imatinib mesylate
Author(s) -
Isik Kaygusuz-Atagunduz,
Tayfur Toptaş,
Perran Fulden Yumuk,
Tulin Fıratlı-Tuğlular,
Mahmut Bayık
Publication year - 2014
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.146095
Subject(s) - imatinib mesylate , medicine , imatinib , myeloid leukemia , breast cancer , oncology , cancer , adjuvant
Imatinib mesylate is the standard treatment of chronic myeloid leukemia (CML). Despite imatinib is being used in the treatment of other malignancies as well, its potential role on de novo tumor growth is not known. Secondary malignancies are rarely seen in patients with CML and particularly in those receiving imatinib. Here, we present a CML patient taking imatinib therapy that was diagnosed to have breast cancer and received adjuvant chemo-and radiotherapy with imatinib. We tried to explain co-occurrence of these rare events by probable pathogenetic mechanisms.